Corrigendum to "Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 years with Cystic Fibrosis and at Least one F508dek Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor". J Pediatr. 2024 Jun 28; 274:114176.
Terlizzi V, Fevola C, Presti S, Castaldo A, Daccò V, Claut L, Sepe A, Majo F, Casciaro R, Esposito I, Vitullo P, Salvi M, Troiani P, Ficili F, Parisi GF, Pantano S, Costa S, Leonetti G, Palladino N, Taccetti G, Bonomi P, Salvatore D.
Terlizzi V, et al. Among authors: salvi m.
J Pediatr. 2024 Nov;274:114228. doi: 10.1016/j.jpeds.2024.114228. Epub 2024 Aug 28.
J Pediatr. 2024.
PMID: 39198099
Free article.
No abstract available.